Who is sponsoring NCT03446209?

NCT03446209 is sponsored by University Hospital Tuebingen.

What drugs are being tested in NCT03446209?

Interventions in NCT03446209: Tocilizumab Infusion RoAcemtra (EU), 0.9% physiological saline.

What condition does NCT03446209 study?

NCT03446209 studies Familial Mediterranean Fever.

Is NCT03446209 still recruiting?

NCT03446209 is currently completed. Last updated 18 November 2020.

Last reviewed 2020-11-18 · How we verify

NCT03446209

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Tocilizumab for the Treatment of Familial Mediterranean Fever

Completed Phase 2 Last updated 18 November 2020

What this trial tests

Phase 2 trial testing Tocilizumab Infusion RoAcemtra (EU) in Familial Mediterranean Fever in 30 participants. Completed in 30 October 2020.

Timeline

23 April 2018

Primary endpoint
30 October 2020

30 October 2020

Quick facts

Lead sponsor	University Hospital Tuebingen
Phase	Phase 2
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	double
Primary purpose	treatment
Enrollment	30
Start date	23 April 2018
Primary completion	30 October 2020
Estimated completion	30 October 2020
Sites	3 locations across Germany

Drugs / interventions tested

Tocilizumab Infusion RoAcemtra (EU) — full drug profile →
0.9% physiological saline — full drug profile →

Conditions studied

Familial Mediterranean Fever — all drugs for Familial Mediterranean Fever →

Sponsor

University Hospital Tuebingen

Who can join

Adults 18 to 64, any sex, with Familial Mediterranean Fever. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Adult patients with Familial Mediterranean Fever, who have active disease

Publications & conference data

6 peer-reviewed publications reference this trial (live from Europe PMC):

Familial Mediterranean fever, from pathogenesis to treatment: a contemporary review
Tufan A, Lachmann HJ. · · 2020 · cited 116× · PMID 32806879 · DOI 10.3906/sag-2008-11
Current Therapeutic Options for the Main Monogenic Autoinflammatory Diseases and PFAPA Syndrome: Evidence-Based Approach and Proposal of a Practical Guide.
Soriano A, Soriano M, Espinosa G, Manna R, et al · · 2020 · cited 49× · PMID 32655539 · DOI 10.3389/fimmu.2020.00865
Interleukin-6 inhibition in the treatment of autoinflammatory diseases.
Koga T, Kawakami A. · · 2022 · cited 20× · PMID 35958618 · DOI 10.3389/fimmu.2022.956795
Tocilizumab for the Treatment of Familial Mediterranean Fever-A Randomized, Double-Blind, Placebo-Controlled Phase II Study.
Henes JC, Saur S, Kofler DM, Kedor C, et al · · 2022 · cited 15× · PMID 36143006 · DOI 10.3390/jcm11185360
Interventions for reducing inflammation in familial Mediterranean fever.
Wu B, Xu T, Li Y, Yin X. · · 2018 · cited 9× · PMID 30338514 · DOI 10.1002/14651858.cd010893.pub3
Interventions for reducing inflammation in familial Mediterranean fever.
Yin X, Tian F, Wu B, Xu T. · · 2022 · cited 6× · PMID 35349164 · DOI 10.1002/14651858.cd010893.pub4

Verify or expand the search:

Other recruiting trials for Familial Mediterranean Fever

Currently open trials in the same condition.

NCT07129538 — Outcomes of Inspiratory Muscle Training in FMF Adolescents · NA · recruiting
NCT07130305 — is There an Effect of Adding Body Vibration to Intake of Vitamin D on Some Outcomes of Familial Mediterranean Fever · NA · recruiting
NCT07130318 — Mediterranean Diet in Familial Mediterranean Fever: Is Fatty Liver Affected by Addition of Aerobic Exercise · NA · recruiting
NCT07128225 — Health-related Quality of Life, Electrocardiographic and Holter Findings in Children With Familial Mediterranean Fever · active not recruiting
NCT06338891 — Can Gluten/Wheat or Other Foods be Responsible for FMF Attacks · recruiting

Other University Hospital Tuebingen trials

Trials by the same sponsor.

NCT07378670 — DEfeating PEnile CAncer-2 · NA · recruiting
NCT07276503 — Verification of a New Predictive Delirium Score in Adults With Elective Cardiac Valve or Bypass Surgery With Perioperati · not yet recruiting
NCT07411365 — Dual-task Cognitive-motor Telerehabilitation in Persons With PD-MCI · NA · not yet recruiting
NCT06953791 — Comparison of Quality of Life During a Flare of Crohn's Disease Treated With Prednisolone or aCDED With PEN in Adult Pat · Phase 2 · recruiting
NCT07378891 — Artificial-Intelligence-based Early Detection of Diabetic Retinopathy (FUNDUS AI) · enrolling by invitation

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03446209 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by University Hospital Tuebingen
Last refreshed: 18 November 2020

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03446209.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing